ProKidney

PROK

Market cap $316M

2.23 USD

-0.01

0.45%

At close Updated Jan 2, 4:00 PM EST

Pre-market

After hours

2.27

+0.04

1.79%

1 day

-0.45%

5 days

-12.89%

1 month

-0.89%

3 months

-19.78%

6 months

285.35%

Year to date

28.9%

1 year

28.9%

5 years

-77.94%

10 years

-77.94%

About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Employees: 204

Healthcare Biotechnology